Tadalafil: Nursing Drug Guide, Nitrate Hypotension & Hold Rules
Tadalafil can treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension, but the bedside never-miss is nitrate or riociguat exposure—combined vasodilation can collapse blood pressure, and labeling requires at least 48 hours after the last dose before nitrates are even considered.
Never give tadalafil with organic nitrates or riociguat. If chest pain requires nitroglycerin after a tadalafil dose, labeling states at least 48 hours should elapse after the last dose before nitrate administration is considered—and only under close supervision with hemodynamic monitoring. Document last tadalafil time on every admission and before any nitrate order.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before any tadalafil dose, confirm no nitrate or riociguat exposure, verify when the last dose was given (48-hour nitrate window), and ensure Cialis and Adcirca are not duplicated—once-daily tadalafil maintains continuous plasma levels that prolong interaction risk.
Most common brand names
Tadalafil appears as Cialis for erectile dysfunction and benign prostatic hyperplasia, and as Adcirca for pulmonary arterial hypertension. Both contain tadalafil—verify product, strength, and indication before every dose to prevent duplicate exposure.
| Product | Typical use | Nursing verification |
|---|---|---|
| Cialis (2.5, 5, 10, 20 mg) | ED as needed, ED once daily, BPH, or ED+BPH once daily | Confirm PRN versus scheduled daily regimen and once-daily maximum for PRN use |
| Adcirca (20 mg tablets) | Pulmonary arterial hypertension | 40 mg once daily = two 20 mg tablets; do not split dose across the day |
| Generic tadalafil | Same active ingredient by indication | Match brand-equivalent strength and schedule; screen for duplicate Cialis + Adcirca orders |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Labeling supports erectile dysfunction, benign prostatic hyperplasia, combined ED+BPH once-daily therapy, and pulmonary arterial hypertension (Adcirca). Review cardiovascular status, coexisting angina therapy, and whether the patient carries home Cialis or Adcirca on admission.
| Indication | Label-based summary |
|---|---|
| Erectile dysfunction (as needed) | Starting dose 10 mg before anticipated sexual activity; may adjust to 5 or 20 mg; not more than once per day |
| Erectile dysfunction (once daily) | Starting dose 2.5 mg once daily; may increase to 5 mg based on response |
| Benign prostatic hyperplasia | 5 mg once daily at approximately the same time each day |
| Pulmonary arterial hypertension | Adcirca 40 mg (two 20 mg tablets) once daily with or without food; do not divide daily dose |
| Not for acute ischemic chest pain | Do not substitute tadalafil for nitrate rescue in active chest pain |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tadalafil inhibits phosphodiesterase type 5, preserving cGMP-mediated smooth-muscle relaxation in penile, prostatic, and pulmonary vascular tissue. The same pathway explains additive hypotension with nitroglycerin, riociguat, alpha-blockers, and substantial alcohol intake.
| Effect | Clinical impact | Nursing implication |
|---|---|---|
| PDE5 inhibition | Increased cGMP and vasodilation | Expect BP-lowering potential, especially with interacting drugs |
| Long half-life (~17.5 h) | Effect may persist up to 36 hours for ED; continuous levels with once-daily use | Nitrate safety window extends at least 48 hours after last dose per labeling |
| Pulmonary vascular relaxation | Improved exercise ability in PAH | Track dyspnea, functional status, and hemodynamic tolerance |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Dosing varies by indication and must never be interchanged. Cialis PRN for ED starts at 10 mg (range 5 to 20 mg) not more than once per day. Once-daily Cialis for ED or BPH typically uses 2.5 to 5 mg. Adcirca for PAH is 40 mg once daily as two 20 mg tablets without dividing the dose across the day.
Missed dose: Once-daily regimens: take when remembered if on schedule; do not double. PRN ED: take before anticipated activity; do not exceed once daily. Institutional protocols and product formulations may vary.
| Population | Label adjustment (summary) |
|---|---|
| CrCl 30–50 mL/min (PRN ED) | Starting 5 mg once daily max; maximum 10 mg not more than once every 48 hours |
| CrCl <30 or hemodialysis (PRN ED) | Maximum 5 mg not more than once every 72 hours; once-daily Cialis not recommended |
| Mild–moderate hepatic impairment (PRN ED) | Maximum 10 mg once per day |
| Potent CYP3A4 inhibitors | PRN: max 10 mg every 72 h; once-daily: max 2.5 mg |
On a small screen, swipe or scroll sideways to see the full table.
Onset, peak, duration, and half-life
| Parameter | Typical value | Nursing relevance |
|---|---|---|
| Onset (ED effect) | About 30 minutes to 2 hours | Counsel realistic timing; effect may last up to 36 hours |
| Half-life | Mean 17.5 hours in healthy subjects | Explains 48-hour nitrate hold window in labeling |
| Once-daily use | Continuous plasma tadalafil levels | Interaction screening must assume ongoing nitrate contraindication |
| Food | May be taken without regard to food | Does not replace indication-specific dose verification |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Complete interaction-focused medication reconciliation including home Cialis, Adcirca, and other PDE5 agents
- Document time of last tadalafil dose and any nitrate use in the past 48 hours
- Obtain baseline BP with standardized blood pressure measurement; use orthostatic blood pressure when symptoms suggest
Contraindications
- Any form of organic nitrate, regularly or intermittently
- Guanylate cyclase stimulators such as riociguat
- Serious hypersensitivity to tadalafil (Cialis or Adcirca)
Important interactions
| Drug or class | Effect | Nursing action |
|---|---|---|
| Organic nitrates | Profound hypotension; contraindicated | Hold tadalafil; if nitrate needed for life-threatening ischemia, ensure ≥48 h since last dose and supervised monitoring per labeling |
| Riociguat | Additive cGMP vasodilation and hypotension | Do not coadminister; escalate for alternative plan |
| Sildenafil or other PDE5 inhibitors | Duplicate class exposure; combinations not studied | Verify only one PDE5 agent; do not combine Cialis and Adcirca |
| Alpha-blockers / antihypertensives / alcohol (≥5 units) | Symptomatic hypotension, dizziness | Stable alpha-blocker therapy before PDE5 initiation; start lowest tadalafil dose; counsel on alcohol limits |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet (Cialis or Adcirca). May be taken with or without food per labeling. Confirm indication, PRN versus daily schedule, and contraindicated co-medications before each dose.
- Verify last tadalafil dose time and 48-hour nitrate safety window
- Document new dizziness or orthostatic symptoms after dosing
- For Adcirca, give full 40 mg daily dose together (two 20 mg tablets)—do not split across the day
- For PRN Cialis, confirm no other tadalafil dose within the same 24-hour period
Labeling instructs patients not to take Cialis with other PDE5 inhibitors, including Adcirca. Duplicate tadalafil exposure increases hypotension, back pain, and priapism risk.
Expected therapeutic response
- ED: improved erectile response with sexual stimulation when using PRN or daily regimens
- BPH: improved lower urinary tract symptoms with daily 5 mg therapy over time
- PAH: improved exercise ability and functional status on Adcirca 40 mg daily
- No progressive hypotension, presyncope, or perfusion decline after dosing
Red flags — Stop and act
Escalate immediately when interaction risk, hemodynamic collapse, or labeling-defined emergencies appear.
- Nitrate ordered or taken within 48 hours of last tadalafil dose without prescriber clearance
- Erection lasting >4 hours (priapism)—emergency urologic evaluation per labeling
- Sudden loss of vision in one or both eyes (possible NAION)
- Sudden hearing loss or ear ringing with dizziness
- Severe hypotension, presyncope, or fainting after dose or nitrate exposure
Adverse effects
Labeling reports common vasodilatory effects (≥2%): headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and limb pain. Hypotension risk rises with nitrates, riociguat, alpha-blockers, or substantial alcohol.
| Adverse effect | Clinical relevance | Nursing response |
|---|---|---|
| Headache, flushing, congestion | Common mild vasodilatory effects | Supportive care; maintain interaction vigilance |
| Back pain / myalgia | Often 12–24 h after dose; usually resolves within 48 h | Differentiate from serious musculoskeletal emergency; document timing |
| Hypotension | High-stakes when interactions present | Hold dose, reposition, trend BP, escalate urgently |
| Priapism (>4 h) | Urologic emergency | Stop PDE5 inhibitor; emergency escalation per protocol |
| Sudden vision or hearing loss | Rare serious warnings | Stop tadalafil; urgent prescriber evaluation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose may cause marked vasodilation, hypotension, and syncope. No specific antidote is listed in the reviewed prescribing information; management is supportive with hemodynamic monitoring and escalation per facility protocol and local poison control or toxicology guidance.
Management priorities
- Stop tadalafil and assess airway, breathing, circulation, and perfusion
- Trend blood pressure and treat symptomatic hypotension per protocol
- Review full medication list for nitrates, riociguat, and duplicate PDE5 exposure
- Escalate for persistent hemodynamic instability, priapism, or neurologic/visual symptoms
Common nursing error: giving nitroglycerin before asking about Cialis
Cialis is commonly used for erectile dysfunction and BPH; Adcirca is used for pulmonary arterial hypertension. Both contain tadalafil and should not appear together on the MAR unless a specialist deliberately documents a plan. Before any nitrate or riociguat order, ask when the last tadalafil dose was given—the 48-hour nitrate contraindication window applies to PRN and once-daily regimens.
Look-alike / sound-alike and error prevention
- Cialis versus Adcirca — same active ingredient, different indications and dosing; never give both
- PRN versus once-daily Cialis — separate MAR logic and patient counseling
- Strength confusion — 5 mg BPH/daily ED is not interchangeable with 20 mg PRN or 40 mg PAH
- Tadalafil versus sildenafil — verify correct PDE5 agent and nitrate hold windows differ (48 h for tadalafil per labeling)
No specific look-alike/sound-alike pair was identified in the reviewed sources beyond PDE5 class confusion, but standard medication-name and strength verification still applies.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Nitrate screen | Ask about SL nitroglycerin, patches, sprays, ointments, and IV nitrates—not only scheduled MAR entries |
| 48-hour window | Record exact time of last tadalafil dose before any nitrate order for chest pain |
| Daily Cialis | Assume continuous nitrate contraindication while therapy is active |
| Crushing/splitting | Not specified in the reviewed prescribing information for all strengths; verify product-specific guidance with pharmacy |
| When to call pharmacy | Duplicate PDE5 orders, unclear indication, renal/hepatic dose questions, or CYP3A4 inhibitor co-therapy |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Cardiovascular disease / heart failure | Greater hypotension sensitivity; sexual activity and vasodilation may not be advisable in unstable disease per labeling warnings |
| Renal impairment | Dose limits apply; once-daily Cialis not recommended if CrCl <30 mL/min or on hemodialysis |
| Hepatic impairment | PRN dose should not exceed 10 mg once daily in mild–moderate impairment; caution with once-daily use |
| Alpha-blocker therapy | Initiate tadalafil at lowest dose only after stable alpha-blocker therapy; BPH combination with alpha-blockers not recommended |
| Priapism risk factors | Sickle cell disease, leukemia, anatomical penile deformity—use caution; erection >4 h is emergency |
| Pregnancy | Not indicated for use in women; pregnancy category B in labeling but inadequate controlled studies in pregnant women |
| Lactation | Not indicated for use in women; consult LactMed and specialist guidance if exposure occurs |
| Pediatrics | Not indicated; safety and efficacy below age 18 not established |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure and orthostatic symptoms before and after dosing
- Time of last tadalafil dose when evaluating any nitrate order
- Indication-specific response: ED effectiveness, BPH symptom trend, or PAH functional status
- Red-flag symptoms: priapism, vision change, hearing change, syncope
Document
- Product (Cialis vs Adcirca), dose, route, time, and indication
- Nitrate and riociguat screen result; 48-hour hold window when relevant
- Held-dose rationale, prescriber/pharmacist notification, and patient teaching provided
Patient teaching
- Never take tadalafil with nitrate products or riociguat; tell all clinicians you use Cialis or Adcirca
- If chest pain occurs after tadalafil, seek immediate medical attention—do not self-treat with nitroglycerin without clinician guidance
- PRN Cialis: not more than once per day; daily Cialis: take same time each day
- Report erection >4 hours, sudden vision or hearing changes, severe dizziness, or collapse immediately
- Do not take Cialis and Adcirca together or with other PDE5 drugs such as sildenafil
- Limit heavy alcohol intake while on tadalafil because combined vasodilation can cause symptomatic hypotension
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Any organic nitrate is active, recently used, or newly ordered within 48 hours of last tadalafil dose
- Riociguat appears on the medication list
- Hypersensitivity to tadalafil, Cialis, or Adcirca is documented
- Symptomatic hypotension, presyncope, or hemodynamic instability before dosing
- Duplicate PDE5 therapy (Cialis + Adcirca, or tadalafil + sildenafil) is suspected
- Order strength or schedule does not match indication (e.g., 40 mg for ED, or divided Adcirca dosing)
- Erection has lasted >4 hours—hold further doses and escalate emergently
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and current product labeling.
Clinical practice integration and workflow
Tadalafil safety hinges on nitrate screening and knowing when the last dose was given. The long half-life and once-daily formulations mean interaction risk persists well beyond the administration moment—especially on med-surg units where chest pain may trigger new nitrate orders.
1. Check-before-you-give protocol
- Confirm product indication: Cialis PRN, Cialis daily, or Adcirca PAH
- Screen nitrates, riociguat, and duplicate PDE5 agents on every pass
- Document last tadalafil dose time and baseline blood pressure
- Verify renal/hepatic dose limits and CYP3A4 inhibitor co-therapy
2. High-alert and safety badge
High-alert interaction risk: nitrates contraindicated; 48-hour window after last doseInteraction screening and last-dose timing are as critical as the dose itself.
3. Clinical workflow: hold and question rules
- Hold tadalafil when any nitrate exposure falls inside the 48-hour window unless supervised emergency plan exists
- Escalate new nitroglycerin orders on patients who take home Cialis or Adcirca before administration
- Question any order combining Cialis and Adcirca or multiple PDE5 inhibitors
4. Critical teach-back questions
- “What must you avoid while taking tadalafil?” (Any nitrate form and riociguat; do not combine Cialis and Adcirca.)
- “When should you seek emergency care?” (Erection >4 hours, sudden vision or hearing loss, collapse, or chest pain after dosing.)
5. Care coordination
Pharmacist: Interaction verification, renal/hepatic dose adjustment, and Cialis versus Adcirca clarification
Prescriber / cardiology or PAH team: Alternative ischemia plan when tadalafil blocks routine nitrate use; PAH regimen optimization
🧠 Quick mental checklist
- When was the last tadalafil dose—and does any new nitrate order fall inside 48 hours?
- Is this Cialis or Adcirca, and is any duplicate PDE5 agent on the list?
- Any riociguat, alpha-blocker, or heavy alcohol use increasing hypotension risk?
- Is baseline BP acceptable and are orthostatic symptoms absent?
- Did I teach priapism, vision/hearing red flags, and nitrate contraindication?
Tadalafil NCLEX practice questions
Work through this NCLEX-style clinical judgment practice set using the case tabs (MAR, labs, history, nursing notes) to catch nitrate orders inside tadalafil’s 48-hour window, prioritize hypotension prevention, and apply matrix urgency to priapism and hemodynamic red flags.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- 62-year-old man admitted with unstable angina evaluation
- Home Cialis 20 mg PRN — last taken yesterday at 2100
- New order: nitroglycerin SL 0.4 mg PRN chest pain
- Scheduled Adcirca 40 mg PO daily appears on MAR from prior PAH clinic list (not verified)
- Creatinine 1.4 mg/dL; eGFR 52 mL/min/1.73 m²
- Troponin pending; BMP otherwise unremarkable
- No acute anemia or electrolyte crisis
- Coronary artery disease; uses sublingual nitroglycerin at home for exertional chest pain
- Reports taking Cialis 20 mg ~30 hours ago for erectile dysfunction
- Denies riociguat; no sildenafil on home list
- Moderate renal impairment (CrCl 30–50 range per recent labs)
- 0400: Patient awakens with substernal pressure; asks for “my nitro pill”
- BP 108/66 sitting; mild lightheadedness reported
- Teaching gap: patient unaware Cialis and nitroglycerin cannot be used together
- Pharmacy not yet consulted on duplicate Adcirca order
Answer key & rationale
Frequently asked questions
Why are nitrates contraindicated with tadalafil?
Tadalafil and organic nitrates both increase cGMP-mediated vasodilation. Concomitant use is contraindicated because it can cause severe hypotension. Labeling states at least 48 hours should elapse after the last tadalafil dose before nitrates are considered in life-threatening situations.
What must nurses verify before giving tadalafil?
Screen for nitrates and riociguat, document time of last dose (48-hour window), check for duplicate PDE5 therapy including Cialis plus Adcirca, review alpha-blockers and BP, and confirm renal/hepatic dose limits.
How does Adcirca dosing differ from Cialis?
Adcirca for PAH is 40 mg (two 20 mg tablets) once daily without dividing the dose. Cialis PRN for ED starts at 10 mg before activity (5–20 mg range), not more than once per day.
Can Cialis and Adcirca be taken together?
No. Labeling instructs patients not to take Cialis with other PDE5 inhibitors, including Adcirca, or with sildenafil (Revatio).
What erection duration requires emergency care?
An erection lasting greater than 4 hours requires emergency medical attention because untreated priapism can cause irreversible damage.
Is there an antidote for tadalafil overdose?
No specific antidote is listed in the reviewed prescribing information. Management is supportive; contact poison control or medical toxicology services per facility protocol and local emergency guidance.
References
-
U.S. National Library of Medicine. Cialis (tadalafil) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6
-
U.S. National Library of Medicine. Adcirca (tadalafil) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae
-
U.S. National Library of Medicine. Tadalafil. Drugs and Lactation Database (LactMed).https://www.ncbi.nlm.nih.gov/books/NBK549843/
-
NICE BNF. Tadalafil. British National Formulary.https://bnf.nice.org.uk/drugs/tadalafil/
-
Webb D. J. et al. Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension. Circulation.https://www.ahajournals.org/doi/10.1161/circulationaha.110.944603
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.